HealthEquity ROI - Return on Investment 2014-2025 | HQY

HealthEquity return on investment for the quarter ending January 31, 2025 was 3.07.

  • HealthEquity average return on investment for 2024 was 2.85, a 4650% increase from 2023.
  • HealthEquity average return on investment for 2023 was 0.06, a 102.97% increase from 2022.
  • HealthEquity average return on investment for 2022 was -2.02, a 2625% decline from 2021.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.

HealthEquity ROI - Return on Investment 2014-2025 | HQY

  • HealthEquity average return on investment for 2024 was 2.85, a 4650% increase from 2023.
  • HealthEquity average return on investment for 2023 was 0.06, a 102.97% increase from 2022.
  • HealthEquity average return on investment for 2022 was -2.02, a 2625% decline from 2021.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$148.1B
Elevance Health (ELV)$90.8B
CVS Health (CVS)$83.7B
Cencora (COR)$47.6B
DiDi Global (DIDIY)$23.1B
Natera (NTRA)$22.8B
ICON (ICLR)$15.8B
Doximity (DOCS)$14.3B
BioMerieux (BMXMF)$14.1B
Revvity (RVTY)$14B
Viatris (VTRS)$13B
Solventum (SOLV)$12.8B
Avantor (AVTR)$12B
CochLear (CHEOY)$11.5B
Medpace Holdings (MEDP)$10.5B
EUROFINS SCIENT (ERFSF)$9.5B
Sonic Healthcare (SKHHY)$8.8B
Charles River Laboratories (CRL)$8.4B
Amplifon S.p.A (AMFPF)$6.2B
Bausch + Lomb (BLCO)$5.7B
Organon (OGN)$3.9B
Sotera Health (SHC)$3.9B
BrightSpring Health Services (BTSG)$3.6B
Surgery Partners (SGRY)$3.3B
GeneDx Holdings (WGS)$3.1B
Concentras Parent (CON)$3B
Alignment Healthcare (ALHC)$2.7B
Teladoc Health (TDOC)$2.4B
Ardent Health Partners (ARDT)$2.1B
Progyny (PGNY)$2B